For years, drug companies had only one way to find out if a new medicine or vaccine works: patient-based clinical trials. But a community of virtual patients is promising to modernize the drug testing process by predicting drugs’ effects.
The resulting studies, called in silico trials, use artificial intelligence (AI)-based simulation technology to mimic human physiology that pharmaceutical companies can use as a proxy for patients. Researchers and clinicians feed drug data into the simulated model to predict the drug’s exposure in patients, and, thereby, test the safety and efficacy of a drug without any consequences on humans and animals…
